For a long time, it was believed that the psychoactivity of tetrahydrocannabinol (THC), which is one of the primary active ingredients in Cannabis sativa L., inhibited any therapeutic potential of this plant.
However, since 2008, over 1,200 scientific publications on the actions of cannabidiol (CBD), which is the other major ingredient of Cannabis, proved that not only does CBD lack the psychoactivity of THC, but also exhibits a wide range of therapeutic benefits.
Due to the popular demand for CBD products, the widespread production and marketing of these treatment options must still undergo various quality control measures to ensure their safety and efficacy for consumers.
ElRoi | Shutterstock
Regulatory status of CBD in the U.S.
By 2020, the projected retail sale of CBD products, which includes hemp, cannabis, and pharmaceuticals, is expected to reach up to $1.9 billion